You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Taking ZEJULA

Convenient once-daily dosing

ZEJULA is a once-daily oral medication, which makes it easy to fit into your schedule. You can plan your treatment around your life, not your life around taking your treatment.1,2

Keep in mind1:

  • While ZEJULA should be taken at the same time each day, you can choose a time that is convenient for you
  • ZEJULA can be taken with or without food, which means that you are not tied to meal schedules
  • If you miss a dose of ZEJULA, you should take the next dose at your regularly scheduled time
  • ZEJULA is easy to travel with. You can keep it in your purse or carry-on bag
  • Store ZEJULA at room temperature between 68°F and 77°F

Your doctor may customize your dose based on your individual needs.1

Image of three ZEJULA capsules of dosage 100 mg each
Image of three ZEJULA capsules of dosage 100 mg each

For all approved uses, your doctor may determine that the appropriate starting dose is 200 mg if you have liver problems. Before taking ZEJULA, tell your doctor about all your medical conditions, including if you have liver problems.

Monitoring how your body responds1

Your healthcare provider will keep a close eye on how ZEJULA is affecting you. He or she will check your blood pressure and heart rate at least weekly for the first two months, then monthly for the first year, and as needed thereafter during treatment with ZEJULA.

Your doctor will also regularly monitor your blood cell counts because ZEJULA can cause changes in your blood cell levels. Complete blood cell counts will be monitored weekly for the first month, monthly for the next 11 months, and periodically after that to ensure that your doctor can respond quickly to any changes.

Table depicting the frequency at which your doctor will monitor your blood pressure, heart rate and blood cell count while you are on ZEJULA
Table depicting the frequency at which your doctor will monitor your blood pressure, heart rate and blood cell count while you are on ZEJULA

*Schedule provided as an example. †Your doctor will determine how often you need blood work.

If your dose has been interrupted or changed, your blood cell counts need to be checked weekly for 4 weeks.

ZEJULA remained effective in the clinical trial, even when doses were adjusted. By working with your doctor to customize your dose of ZEJULA, you may be able to stay on and benefit from treatment longer.1,3,4

Managing potential side effects1

It's important to tell your doctor about any side effects that you experience while taking ZEJULA so he or she can help you manage them. Together, you can work to find the right dose for you. For example, if you experience nausea, your doctor may suggest taking ZEJULA before bed.1

If you experience side effects, your doctor may interrupt your treatment with ZEJULA for up to 28 days or reduce the number of capsules that you take each day. This dose adjustment or interruption is to allow your blood counts or other severe side effects to improve. Your doctor may ask you to make adjustments in the schedule of your blood tests and will determine when you can resume taking ZEJULA.1 

Support
During Treatment

Find resources that may help you access and pay for ZEJULA

Get Access and Support

Commonly
Used Terms

Get more detailed definitions of commonly used terms in ovarian cancer treatment

View the Glossary

ZEJULA
MY WAY

Get support whether you're already taking ZEJULA or still deciding if it's right for you

Sign up now

References: 1. ZEJULA (niraparib) Prescribing Information. GlaxoSmithKline; 2021. 2. Ferrell B, Smith SL, Cullinane CA, Melancon C. Psychological well being and quality of life in ovarian cancer survivors. Cancer. 2003;98(5):1061-1071. 3. Data on file. GlaxoSmithKline. 4. Wang J, Zhang Z-Y, Mansoor R, et al. The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: results from the ENGOT-OV16/NOVA trial. Poster presented at: Annual Congress of the European Society for Medical Oncology; September 8-12, 2017; Madrid, Spain. 

Back to Top